Sanofi, GDF SUEZ boost partnership to reduce global energy footprint
The initial three-year term contract has been extended to five years, which will cover sites in the US, Canada, Mexico, Brazil, China, and Singapore, and comes after the
Swedish Orphan Biovitrum (Sobi) has received a complete response letter from the US Food and Drug Administration (FDA) regarding its biologics licence application for nanoencapsulated sirolimus plus pegadricase (NASP), an investigational therapy intended for adults with uncontrolled gout.
The Supplemental New Drug Application (sNDA) of Mycamine is also indicated for patients with prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplants (HSCT). Astellas Pharma
Under the terms of the agreement, ADC Therapeutics has licensed a VivaMab antibody, VM101, produced using BioAtla’s Express Humanization, Comprehensive Positional Evolution, Combinatorial Protein Synthesis affinity and functional
Albiglutide is an investigational glucagon-like peptide receptor agonist (GLP-1), which is an investigational once a week treatment for type 2 diabetes. Comprising eight individual studies (Harmony 1 to